| | 
Part, Chapter, Paragraph
1 II, 4. 1 | increase was from 77 to 81. The figures are somewhat
2 II, 4. 1 | women. These years represent 81% and 77% of the total life
3 II, 5. 5. 2| with dementia in 2020 and 81 million by 2040. These predictions
4 II, 5. 5. 3| shows an incidence rate of 81,1 per 100.000 (Hoek and
5 II, 5. 5. 3| examination~278/51~ ~199/235~ ~81/47~6.2/5.1~ ~3.9/5.2~ ~3.
6 II, 5. 5. 3| still at work compared to 81.5% of the healthy population.
7 II, 5. 6. 6| 2000-2010. Ann Rheum Dis 59:81-82~Woolf AD (2007): What
8 II, 5. 6. 6| Bull World Health Organ 81(9):646-56~Woolf AD and Akesson
9 II, 5. 8. 7| or COPD. Chest 2004; 126: 81-89.~ ~Stratelis G, Jakobsson
10 II, 5. 9. 4| 0001), eczema (1.42:1 to 0.81:1 P <0.0001) and hay fever (
11 II, 5. 11. 3| Dermatitis, 1997;37(2):78-81.~H Suzuki, Nickel and gold
12 II, 5. 11. 7| Acta Derm Venereol 2001;81:193-7.~ ~Boyle P, Dorè JF,
13 II, 5. 11. 7| Acta Derm Venereol 2001;81:268–272.~ ~Weismann K, Krakauer
14 II, 5. 14. 8| Quintessence Publishing Co. 2004:81–92.~Bourgeois DM (2004):
15 II, 5. 14. 8| Oral Epidemiol 2005; 33: 81–92.~Selwitz RH, Ismail AI,
16 II, 6. 3. 6| 25 countries. Slovakia (9.81 per 100 000) and Latvia (
17 II, 9. 2. 7| diseases. Semin Perinatol. 28:81-7.~ ~Social Issues Research
18 II, 9. 4. 1| women in the EU is currently 81.2 years compared to 75.1
19 III, 10. 2. 1| Quintessence Publishing Co., 2004:81–92.~ ~Bourgeois DM, Llodra
20 III, 10. 5. 2| intermediate settings and at 0.81 for rural settings when
21 III, 10. 5. 2| rather similar (0.94 and 0.81, respectively) also for
22 IV, 11. 1. 5| for most adverse events (81.8%) (Wilson et al, 1995).
23 IV, 11. 5. 4| increasing public awareness. 81% of European citizens support
24 IV, 11. 6. 2| total spending from about 81% to 86%. While in some countries,
25 IV, 11. 6. 5| Health Systems and Policies: 81-140.~ ~Garfield FB, Garfield
26 IV, 11. 6. 5| Outcomes Research 5(1): 81-93.~ ~Mrazek M, Mossialos
|
|
| |
